参麦注射液联合西药对急性心肌梗死患者PCI 术后无复流的疗效观察及对心肌损伤、氧化应激的影响
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R542.22

基金项目:

浙江省湖州市科技局公益性应用研究项目(2019GY12)


Curative Effect of Shenmai Injection Combined with Western Medicine on No-Reflow After PCI in Patients with Acute Myocardial Infarction and Its Effect on Myocardial Injury and Oxidative Stress
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察参麦注射液联合西药对急性心肌梗死(AMI) 患者行经皮冠脉介入治疗(PCI) 术后无复流的疗效及对心肌损伤、氧化应激的影响。方法:选取82 例行PCI 术的AMI 患者作为研究对象,按治疗方式不同将其分为对照组及观察组各41 例。对照组给予西药治疗,观察组术前在对照组基础上加用替罗非班注射液,术后在对照组基础上静脉滴注参麦注射液。比较2 组无复流发生率,比较2 组手术前后心肌酶指标[心肌肌钙蛋白I (cTnI)、肌酸激酶同工酶(CK-MB)] 水平,氧化应激指标[超氧化物歧化酶(SOD)、丙二醛(MDA)] 的变化,比较2 组不良心血管事件发生率。结果:术后,观察组无复流发生率为21.95%,对照组为43.90%,2 组比较,差异有统计学意义(P<0.05)。术后,2 组cTnI、CK-MB 水平均较术前下降,观察组cTnI、CK-MB 水平均低于对照组,差异均有统计学意义(P<0.05)。术后,2 组SOD 水平均较术前升高,MDA 水平均较术前下降,差异均有统计学意义(P<0.05);术后,观察组SOD 水平高于对照组,MDA 水平低于对照组,差异均有统计学意义(P<0.05)。观察组不良心血管事件发生率为7.32%,对照组不良心血管事件发生率为24.39%,2 组比较,差异有统计学意义(P<0.05)。结论:参麦注射液联合西药可有效降低行PCI 术的AMI 患者术后无复流发生率,降低心肌损伤程度,有效调节患者氧化应激状态,治疗方案的安全性较高。

    Abstract:

    Abstract:Objective:To observe the curative effect of the therapy of Shenmai injection combined with western medicine on no- reflow after percutaneous coronary intervention(PCI) in patients with acute myocardial infarction(AMI) and its effect on myocardial injury and oxidative stress. Methods: A total of 82 AMI patients who received PCI were selected as the research objects and divided into the control group and the observation group according to different treatment methods, with 41 cases in each group. The control group was treated with western medicine,and the observation group was additionally treated with tirofiban injection based on the treatment of the control group before PCI and was treated with intravenous infusion of Shenmai injection based on the treatment of the control group after PCI. The incidence of noreflow was compared between the two groups. Before and after PCI,the changes of levels of myocardial enzyme indexes,including cardiac troponin I(cTnI) and creatine kinase-MB(CK-MB),and oxidative stress indexes,including superoxide dismutase(SOD) and malondialdehyde(MDA),were compared between the two groups. The incidence of adverse cardiac events was compared between the two groups. Results: After PCI,the incidence of no-reflow was 21.95% in the observation group and was 43.90% in the control group, the difference being significant(P<0.05). After PCI, the levels of cTnI and CK- MB in the two groups were decreased when compared with those before PCI, and the above two levels in the observation group were lower than those in the control group,differences being significant(P<0.05). After PCI,the levels of SOD in the two groups were increased when compared with those before PCI,and the levels of MDA were decreased,differences being significant(P<0.05);after PCI,the level of SOD in the observation group was higher than that in the control group,and the level of MDA in the observation group was lower,differences being significant(P<0.05). The incidence of adverse cardiac events was 7.32% in the observation group and was 24.39% in the control group, the difference being significant(P<0.05). Conclusion:The therapy of Shenmai injection combined with western medicine can effectively reduce the incidence of no-reflow after PCI in AMI patients,reduce the degree of myocardial injury,and effectively regulate the oxidative stress state of patients,with high safety.

    参考文献
    相似文献
    引证文献
引用本文

曹建成,郭璐,孙启银.参麦注射液联合西药对急性心肌梗死患者PCI 术后无复流的疗效观察及对心肌损伤、氧化应激的影响[J].新中医,2022,54(15):48-52

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-08-04
  • 出版日期: